✨ Onyx Summary Geron reported third-quarter 2025 revenue of $47.2 million, up 67% year over year, driven by continued commercialization of RYTELO for lower-risk myelodysplastic syndromes, with a net loss of $18.4 million and $421.5 million in cash. The company completed enrollment in its Phase 3 IMpactMF trial
✨ Onyx Summary Keros Therapeutics reported a third-quarter 2025 net loss of $7.3 million, significantly reduced from $53.0 million a year earlier, driven by revenue from its licensing agreement with Takeda. The company ended the quarter with $693.5 million in cash and plans to return $375 million to
✨ Onyx Summary Foghorn Therapeutics reported third-quarter 2025 collaboration revenue of $8.2 million and a net loss of $15.8 million, ending the quarter with $180.3 million in cash and a runway extending into 2028. The company advanced its oncology pipeline—including FHD-909 in Phase 1 with Lilly and
✨ Onyx Summary Guardant Health reported new real-world data showing a 95% adherence rate for its FDA-approved Shield blood-based colorectal cancer screening test, significantly higher than traditional colonoscopy or stool-based methods. Additional findings from clinics in Appalachia showed Shield increased overall screening rates from 45% to 90%, reinforcing its role in
✨ Onyx Summary Guardant Health priced an upsized public offering of 3,333,333 shares of common stock at $90 per share, increasing the deal from the previously announced $250 million to approximately $300 million in gross proceeds, with underwriters granted an option to purchase up to 499,999 additional shares.
✨ Onyx Summary Guardant Health priced an upsized $350 million private offering of 0% convertible senior notes due 2033, increased from $300 million, with an option for an additional $52.5 million and a conversion price of approximately $121.50 per share—a 35% premium to its concurrent equity offering. The
✨ Onyx Summary Lexicon Pharmaceuticals announced that new data from three studies of sotagliflozin will be presented at the 2025 American Heart Association Scientific Sessions and the Hypertrophic Cardiomyopathy Society conference in New Orleans. The presentations will highlight sotagliflozin’s effects in heart failure and hypertrophic cardiomyopathy, reinforcing its potential differentiation
✨ Onyx Summary Recursion announced its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11 and the Jefferies Global Healthcare Conference in London on November 18, 2025. Live webcasts of both events will be available on the company’s investor relations website. Salt Lake City, Nov. 04, 2025
“We can regulate any gene, anywhere,” says CEO Dr. Amber Salzman, whose Epicrispr team is pioneering epigenetic editing - a precise, non-cutting approach - to transform neuromuscular disease treatment through durable, targeted control of gene activity.
✨ Onyx Summary Geron announced that CEO Harout Semerjian will participate in fireside chats at the Stifel 2025 Healthcare Conference on November 11 and the 8th Annual Evercore Healthcare Conference on December 2. Live and archived webcasts of both sessions will be available on the company’s investor relations website. FOSTER
✨ Onyx Summary Phathom Pharmaceuticals announced dosing of the first patient in its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA (vonoprazan) tablets as a potential treatment for eosinophilic esophagitis in adults. The randomized, placebo-controlled study aims to assess VOQUEZNA’s efficacy and safety as a non-steroidal oral therapy for EoE, with topline
✨ Onyx Summary enGene Holdings was named to BioSpace’s 2026 Best Places to Work list, recognizing it among the top 50 U.S. life sciences employers for workplace culture and employee engagement. The honor reflects enGene’s continued growth and mission-driven focus as it advances its late-stage non-viral gene therapy,
✨ Onyx Summary Guardant Health launched a $250 million underwritten public offering of its common stock, with an additional $37.5 million option for underwriters, to be managed by Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities. Proceeds, alongside funds from a concurrent $300 million convertible notes offering, will be used
✨ Onyx Summary Guardant Health announced plans to offer $300 million in convertible senior notes due 2033 in a private placement to qualified institutional buyers, with an option for initial purchasers to buy an additional $45 million in notes. The company will use proceeds from this and a concurrent $250 million
✨ Onyx Summary Kyverna Therapeutics closed a $150 million non-dilutive loan facility with Oxford Finance, drawing an initial $25 million to support its late-stage autoimmune disease programs. The financing extends Kyverna’s cash runway into 2027 as it advances KYV-101 toward a Phase 3 trial in myasthenia gravis, prepares a BLA
✨ Onyx Summary Geron announced five presentations at the 2025 American Society of Hematology Annual Meeting, including new clinical and translational data on RYTELO (imetelstat) in lower-risk myelodysplastic syndromes and myelofibrosis. The presentations highlight long-term efficacy results from the Phase 3 IMerge trial and new analyses linking imetelstat’s biological activity
